Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke

Journal of the American College of Cardiology

Volumn 67, Issue 25, 2016, Pages 2913-2923

  Hsu, Jonathan C ^a   Maddox, Thomas M ^b   Kennedy, Kevin ^c   Katz, David F ^b   Marzec, Lucas N ^b   Lubitz, Steven A ^d   Gehi, Anil K ^e   Turakhia, Mintu P ^f   Marcus, Gregory M ^g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aspirin; CHA2DS2 VASc score; CHADS2 score; thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN; FIBRINOLYTIC AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CARDIOLOGY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL PRACTICE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EMBOLISM; FEMALE; GENDER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; COMPARATIVE STUDY; COMPLICATION; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DRUG PRESCRIPTIONS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RISK ASSESSMENT; RISK FACTORS; STROKE; WARFARIN;

EID: 84994351190     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.581     Document Type: Article

References (26)

1. 1 Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001), 2370–2375.
2. 2 Gage, B.F., Waterman, A.D., Shannon, W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
3. 3 Lip, G.Y.H., Nieuwlaat, R., Pisters, R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137 (2010), 263–272.
4. 4 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
5. 5 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
6. 6 Aguilar, M.I., Hart, R., Pearce, L.A., Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev(3), 2007 CD006186.
7. 7 Chan, P.S., Maddox, T.M., Tang, F., et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol 108 (2011), 1136–1140.
8. 8 Chan, P.S., Oetgen, W.J., Buchanan, D., et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol 56 (2010), 8–14.
9. 9 Messenger, J.C., Ho, K.K.L., Young, C.H., et al., NCDR Science and Quality Oversight Committee Data Quality Workgroup. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol 60 (2012), 1484–1488.
10. 10 Fuster, V., Rydén, L.E., Cannom, D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48 (2006), 854–906.
11. 11 Camm, A.J., Lip, G.Y.H., De Caterina, R., et al., ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 33 (2012), 2719–2747.
12. 12 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), 2246–2280.
13. 13 Raghunathan, T.E., Solenberger, P.W., Van Hoewyk, J., IVEware: Imputation and Variance Estimation Software. 2002, Survey Methodology Program, Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI.
14. 14 Zou, G., A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159 (2004), 702–706.
15. 15 Go, A.S., Hylek, E.M., Borowsky, L.H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131 (1999), 927–934.
16. 16 Glazer, N.L., Dublin, S., Smith, N.L., et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 167 (2007), 246–252.
17. 17 Kakkar, A.K., Mueller, I., Bassand, J.P., et al., GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One, 8, 2013 e63479.
18. 18 van Walraven, C., Hart, R.G., Singer, D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288 (2002), 2441–2448.
19. 19 Vandvik, P.O., Lincoff, A.M., Gore, J.M., et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:Suppl (2012), e637S–e668S.
20. 20 Hansen, M.L., Sørensen, R., Clausen, M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
21. 21 Thompson, L.E., Maddox, T.M., Bradley, S.M., et al. Abstract 14594: gender differences in use of anti-coagulant for atrial fibrillation: a report from the NCDR (abstr). Circulation, 132, 2015 A14594.
22. 22 Steinberg, B.A., Kim, S., Piccini, J.P., et al., ORBIT-AF Investigators and Patients. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 128 (2013), 721–728.
23. 23 O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), e78–e140.
24. 24 You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:Suppl (2012), e531S–e575S.
25. 25 Pisters, R., Lane, D.A., Nieuwlaat, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
26. 26 Olesen, J.B., Lip, G.Y.H., Lindhardsen, J., et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 106 (2011), 739–749.